Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | HAT1 | O14929 | 3/20 | 0.33 |
| ▸ | EP300 | Q09472 | 3/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811266 | 0.94 | PTGER4 (0.36) | PTGER4TSHRMAPK1PLA2G4ALTB4R | |
| SCHEMBL4815680 | 0.91 | PTPRC (0.37) | PTGER4TSHRMAPK1PLA2G4ALTB4R | |
| SCHEMBL5168021 | 0.89 | PTGER4 (0.38) | PTGER4PLA2G4ALTB4RHAT1EP300 | |
| SCHEMBL4812930 | 0.89 | PLA2G4A (0.41) | TSHRMAPK1PLA2G4ALTB4RCYSLTR2 | |
| SCHEMBL4815675 | 0.87 | ROCK2 (0.42) | PTGER4TSHRMAPK1ROCK2 | |
| SCHEMBL4812944 | 0.86 | PLA2G4A (0.38) | TSHRMAPK1PLA2G4ALTB4RCYSLTR2 | |
| SCHEMBL4813338 | 0.86 | P2RX3 (0.40) | PTGER4TSHRMAPK1ROCK2 | |
| SCHEMBL4815505 | 0.86 | TSHR (0.36) | TSHRMAPK1PLA2G4ALTB4RHDAC8 | |
| SCHEMBL4805310 | 0.84 | PTGER4 (0.35) | PTGER4PLA2G4ALTB4R | |
| SCHEMBL4815125 | 0.83 | TSHR (0.33) | TSHRMAPK1PLA2G4ALTB4RHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | F12, F11, F2 | PTGER4 697/4885TSHR 2197/4885MAPK1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.